CL2018000357A1 - Polipéptidos mrka, anticuerpos y usos los mismos - Google Patents

Polipéptidos mrka, anticuerpos y usos los mismos

Info

Publication number
CL2018000357A1
CL2018000357A1 CL2018000357A CL2018000357A CL2018000357A1 CL 2018000357 A1 CL2018000357 A1 CL 2018000357A1 CL 2018000357 A CL2018000357 A CL 2018000357A CL 2018000357 A CL2018000357 A CL 2018000357A CL 2018000357 A1 CL2018000357 A1 CL 2018000357A1
Authority
CL
Chile
Prior art keywords
klebsiella
antibodies
mrka
fragments
same
Prior art date
Application number
CL2018000357A
Other languages
English (en)
Spanish (es)
Inventor
Qun Wang
Saravanan RAJAN
Chew-Shun Chang
Thompson Jenny Heidbrink
Hung-Yu Lin
Charles Kendall Stover
Meghan Pennini
William Dall'acqua
Partha S Chowdhury
Xiaodong Xiao
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CL2018000357A1 publication Critical patent/CL2018000357A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CL2018000357A 2015-08-24 2018-02-08 Polipéptidos mrka, anticuerpos y usos los mismos CL2018000357A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US201562238828P 2015-10-08 2015-10-08

Publications (1)

Publication Number Publication Date
CL2018000357A1 true CL2018000357A1 (es) 2018-07-20

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000357A CL2018000357A1 (es) 2015-08-24 2018-02-08 Polipéptidos mrka, anticuerpos y usos los mismos

Country Status (16)

Country Link
US (2) US20170073397A1 (https=)
EP (1) EP3341004A4 (https=)
JP (1) JP2018527924A (https=)
KR (1) KR20180042300A (https=)
CN (1) CN107921086A (https=)
AU (1) AU2016313653A1 (https=)
BR (1) BR112018003252A2 (https=)
CA (1) CA2995387A1 (https=)
CL (1) CL2018000357A1 (https=)
CO (1) CO2018001985A2 (https=)
HK (1) HK1252350A1 (https=)
IL (1) IL257434A (https=)
MX (1) MX2018001964A (https=)
RU (1) RU2018107056A (https=)
TW (1) TW201718626A (https=)
WO (1) WO2017035154A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
US11117956B2 (en) 2016-10-19 2021-09-14 Medimmune, Llc Anti-O1 antibodies and uses thereof
WO2018237221A1 (en) * 2017-06-23 2018-12-27 Nosocomial Vaccine Corporation IMMUNOGENIC COMPOSITIONS
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725B (zh) * 2023-07-06 2025-11-04 深圳康泰生物制品股份有限公司 肺炎克雷伯菌的FimA的抗原表位肽及其应用
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
AU7470300A (en) * 1999-08-11 2001-03-05 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
CA2541360A1 (en) * 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2489673A3 (en) * 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
US20140011691A1 (en) * 2010-10-26 2014-01-09 Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting for and on Behalf of Az. Morphology and protein specific reagents as diagnostics for neurodegenerative diseases
BR112014011028B1 (pt) * 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição

Also Published As

Publication number Publication date
US20190062411A1 (en) 2019-02-28
KR20180042300A (ko) 2018-04-25
CA2995387A1 (en) 2017-03-02
EP3341004A1 (en) 2018-07-04
CO2018001985A2 (es) 2018-11-22
MX2018001964A (es) 2018-06-19
TW201718626A (zh) 2017-06-01
AU2016313653A1 (en) 2018-04-12
US20170073397A1 (en) 2017-03-16
JP2018527924A (ja) 2018-09-27
HK1252350A1 (zh) 2019-05-24
CN107921086A (zh) 2018-04-17
EP3341004A4 (en) 2019-05-15
IL257434A (en) 2018-04-30
RU2018107056A (ru) 2019-09-26
BR112018003252A2 (pt) 2018-09-25
WO2017035154A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
CL2018000357A1 (es) Polipéptidos mrka, anticuerpos y usos los mismos
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CL2018000042A1 (es) Anticuerpos de unión a tau
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
CL2018000043A1 (es) Anticuerpos de unión a tau
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX377753B (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
IL261140A (en) Anti-tnfalpha-antibodies and functional fragments thereof
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
MX392761B (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
IL261031A (en) Anti-tnfalpha-antibodies and functional fragments thereof